Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer.
Kamaraju S, Fowler AM, Weil E, Wisinski KB, Truong TH, Lehr M, Chaudhary LN, Cheng YC, Chitambar CR, Rui H, Yee D, Lange C. Kamaraju S, et al. Among authors: chaudhary ln. Endocrinology. 2021 Aug 1;162(8):bqab060. doi: 10.1210/endocr/bqab060. Endocrinology. 2021. PMID: 33735382 Review.
High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer.
Chervoneva I, Peck AR, Sun Y, Yi M, Udhane SS, Langenheim JF, Girondo MA, Jorns JM, Chaudhary LN, Kamaraju S, Bergom C, Flister MJ, Hooke JA, Kovatich AJ, Shriver CD, Hu H, Palazzo JP, Bibbo M, Hyslop T, Nevalainen MT, Pestell RG, Fuchs SY, Mitchell EP, Rui H. Chervoneva I, et al. Among authors: chaudhary ln. JCO Precis Oncol. 2023 Jan;7:e2100498. doi: 10.1200/PO.21.00498. JCO Precis Oncol. 2023. PMID: 36652667 Free PMC article.
Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy.
Chaudhary LN, Jorns J, Sun Y, Cheng YC, Kamaraju S, Burfeind J, Gonyo M, Kong A, Patten C, Yen T, Cortina C, Carson E, Johnson N, Bergom C, Tsaih SW, Banerjee A, Wang Y, Chervoneva I, Weil E, Chitambar CR, Rui H. Chaudhary LN, et al. Res Sq [Preprint]. 2023 Apr 7:rs.3.rs-2777910. doi: 10.21203/rs.3.rs-2777910/v1. Res Sq. 2023. Update in: Breast Cancer Res Treat. 2023 Oct;201(3):387-396. doi: 10.1007/s10549-023-07038-3 PMID: 37066270 Free PMC article. Updated. Preprint.
Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy.
Chaudhary LN, Jorns JM, Sun Y, Cheng YC, Kamaraju S, Burfeind J, Gonyo MB, Kong AL, Patten C, Yen T, Cortina CS, Carson E, Johnson N, Bergom C, Tsaih SW, Banerjee A, Wang Y, Chervoneva I, Weil E, Chitambar CR, Rui H. Chaudhary LN, et al. Breast Cancer Res Treat. 2023 Oct;201(3):387-396. doi: 10.1007/s10549-023-07038-3. Epub 2023 Jul 17. Breast Cancer Res Treat. 2023. PMID: 37460683 Free PMC article.
National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial.
Rogers C, Cobb AN, Lloren JIC, Chaudhary LN, Johnson MK, Huang CC, Teshome M, Kong AL, Singh P, Cortina CS. Rogers C, et al. Among authors: chaudhary ln. Breast Cancer Res Treat. 2024 Jan;203(2):317-328. doi: 10.1007/s10549-023-07114-8. Epub 2023 Oct 20. Breast Cancer Res Treat. 2024. PMID: 37864105
30 results